- Q1 2022 Financial Highlights:
- Total net revenue was $16.4 million
- Gross margin was 56% of total revenue
- Post Quarter End:
- NaviNet Open Won MedTech Breakthrough “Healthcare Insurance Innovation Award.” This is the second year in a row that a NantHealth product has been recognized for this award
Morrisville, NC – May 5, 2022 — NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today reported financial results for its first quarter ended March 31, 2022.
“We are pleased to start the year with positive momentum, with our 2022 first quarter revenue increasing over the previous quarter,” said Ron Louks, Chief Operating Officer, NantHealth.
“To help drive further growth, we continue to invest in the development of our products and services, including the expansion of our cloud and data analytics capabilities. These investments are delivering results in multiple ways, including the launch of several new applications on our new cloud platform. Eviti Connect expansion continued with Autoimmune Diseases and our NantHealth Partner Portal which added on-demand customer access to interactive reporting. We are also seeing continued interest in our data enrichment services, as well as pilot programs for The OpenNMS Group Inc.’s cloud services.”
Software and Services Q1 Highlights:
- Clinical Decision Support (Eviti®):
- Signed a multi-year renewal with a leading nonprofit, multi-state health plan serving government sponsored programs. The agreement significantly expands the scope of Eviti Connect for Oncology services provided to the plan, including the addition of full delegation services and evidence-based radiation oncology care
- Expanded full delegation capabilities to include radiation oncology services in addition to medical oncology, enabling customers to assign prior authorization decisions to NantHealth
- New functionality that allows health plan customers to approve and assign a prior authorization Eviti code to portions of a treatment plan, eliminating the need for complete plan resubmission and speeding up treatment to patients
- Payer Engagement (NaviNet®):
- Received HITRUST certification, a highly stringent benchmark that ensures NantHealth continues to meet key regulations and industry-defined security requirements. This places NantHealth and NaviNet Open in an elite group of organizations worldwide that have earned this status for information security
- In May 2022, won the MedTech Breakthrough “Healthcare Insurance Innovation Award,” recognized for the platform’s innovative ability to break through digital health and technology markets
- Enhanced NaviNet Open Authorizations with new processes for automating the collection of additional procedure code modifiers and reducing the need for manual follow-up by the health plan
- Network Monitoring and Management (The OpenNMS Group, Inc.):
- Released OpenNMS Meridian 2022, the optimized and hardened version of the OpenNMS platform available to annual maintenance subscribers for use in production environments. Meridian 2022 features enhanced security, improved analytics for NetFlow processing, simplified Minion communication and enhanced geolocation with IP addresses
- Signed several new professional services agreements with customers using the Horizon and Meridian versions of the OpenNMS platform. This work in collaboration with customers helps to improve the extensibility, reliability, and scalability of the platform for the entire user community
- Completed global delivery of 1U hardware appliances, expanding the existing hardware appliance beta program with a large consumer electronics retailer
First Quarter Financial Results: 2022 vs 2021
For the 2022 first quarter:
- Total net revenue was $16.4 million compared with $16.2 million.
- Gross profit was $9.2 million, or 56% of total net revenue, compared with $9.1 million, or 56% of total net revenue.
- Selling, general and administrative (SG&A) expenses increased to $15.0 million from $12.5 million.
- Research and development (R&D) expenses increased to $5.7 million from $5.0 million.
- Net loss from continuing operations, net of tax, was $16.0 million, or $0.14 per share, compared with $15.4 million, or $0.14 per share.
- On a non-GAAP basis, net loss from continuing operations was $12.2 million, or $0.11 per share, compared with $9.6 million, or $0.09 per share.
- At March 31, 2022, cash and cash equivalents totaled $16.1 million.
Conference Call Information and Forward-Looking Statements
Later today, the company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to review its results of operations for the first quarter ended March 31, 2022. The conference call will be available to interested parties by dialing 800-920-5526 from the U.S. or Canada, or 212-231-2907 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.
Discussion during the conference call may include forward-looking statements regarding topics such as the company’s financial status and performance, regulatory and operational developments, and other comments the company may make about its future plans or prospects in response to questions from participants on the conference call.
Use of Non-GAAP Financial Measures
This news release contains references to Non-GAAP financial measures, including adjusted net loss and adjusted net loss per share, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). The Company’s management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor’s overall understanding of the financial results for the Company’s core business. Additionally, it provides a basis for the comparison of the financial results for the Company’s core business between current, past and future periods. Other companies may define these measures in different ways. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP. Non-GAAP per share numbers are calculated based on one class of common stock and do not incorporate the effects, if any, of using the two-class method.
About NantHealth, Inc.
NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret and visualize complex and highly sensitive information, NantHealth enables customers in healthcare, life sciences, logistics, telecommunications and other industries to automate, understand and act on data while keeping it secure and scalable. NantHealth’s product portfolio comprises the latest technology in payer/provider collaboration platforms for real-time coverage decision support (Eviti and NaviNet), and data solutions that provide multi-data analysis, reporting and professional services offerings (Quadris). The OpenNMS Group, Inc., a NantHealth subsidiary, helps businesses monitor and manage network health and performance. For more information, visit nanthealth.com, follow us on Twitter, Facebook, LinkedIn and YouTube and subscribe to our blog.
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; our ability to grow the market for our software and data solutions; successfully enhancing our software and data solutions to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to integrate The OpenNMS Group, Inc. into our operations; our use and distribution of open source software; our ability to obtain necessary regulatory approvals, certifications and licenses; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.
FINANCIAL TABLES FOLLOW
NantHealth, Inc.
Consolidated Balance Sheets
(Dollars in thousands)
| March 31, 2022 |
December 31, 2021 |
||
| (Unaudited) | |||
| Assets | |||
| Current assets | |||
| Cash and cash equivalents | $ 16,078 | $ 29,084 | |
| Accounts receivable, net | 5,025 | 5,810 | |
| Related party receivables, net | 505 | 506 | |
| Prepaid expenses and other current assets | 4,518 | 4,010 | |
| Total current assets | 26,126 | 39,410 | |
| Property, plant, and equipment, net | 11,956 | 12,366 | |
| Goodwill | 98,333 | 98,333 | |
| Intangible assets, net | 36,807 | 39,039 | |
| Related party receivable, net of current | 1,012 | 1,012 | |
| Operating lease right-of-use assets | 5,673 | 6,048 | |
| Other assets | 1,494 | 1,620 | |
| Total assets | $ 181,401 | $ 197,828 | |
| Liabilities and Stockholders’ Equity | |||
| Current liabilities | |||
| Accounts payable | $ 5,288 | $ 3,204 | |
| Accrued and other current liabilities | 12,712 | 16,358 | |
| Deferred revenue | 2,704 | 2,440 | |
| Related party payables, net | 4,302 | 5,161 | |
| Notes payable | — | 782 | |
| Total current liabilities | 25,006 | 27,945 | |
| Deferred revenue, net of current | 1,793 | 2,024 | |
| Related party liabilities | 40,136 | 38,278 | |
| Related party promissory note | 112,666 | 112,666 | |
| Related party convertible note, net | 62,285 | 62,268 | |
| Convertible notes, net | 74,623 | 74,603 | |
| Deferred income taxes, net | 1,680 | 1,775 | |
| Operating lease liabilities | 5,711 | 6,248 | |
| Other liabilities | 34,098 | 34,013 | |
| Total liabilities | 357,998 | 359,820 | |
| Stockholders’ deficit | |||
| Common stock, $0.0001 par value per share, 750,000,000 shares authorized; 115,550,244 and 115,505,244 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 12 | 12 | |
| Additional paid-in capital | 892,546 | 891,105 | |
| Accumulated deficit | (1,068,847) | (1,052,897) | |
| Accumulated other comprehensive loss | (308) | (212) | |
| Total stockholders’ deficit | $ (176,597) | $ (161,992) | |
| Total liabilities and stockholders’ deficit | $ 181,401 | $ 197,828 |
NantHealth, Inc.
Consolidated Statements of Operations
(Dollars in thousands, except per share amounts)
(Unaudited)
| Three Months Ended
March 31, |
|||
| 2022 | 2021 | ||
| Revenue | |||
| Software-as-a-service related | $ 15,771 | $ 15,757 | |
| Maintenance | 464 | 383 | |
| Professional services | 138 | 27 | |
| Total software-related revenue | 16,373 | 16,167 | |
| Other | — | 3 | |
| Total net revenue | 16,373 | 16,170 | |
| Cost of Revenue | |||
| Software-as-a-service related | 5,563 | 5,535 | |
| Maintenance | 369 | 207 | |
| Professional services | — | 7 | |
| Amortization of developed technologies | 1,247 | 1,247 | |
| Total software-related cost of revenue | 7,179 | 6,996 | |
| Other | — | 47 | |
| Total cost of revenue | 7,179 | 7,043 | |
| Gross Profit | 9,194 | 9,127 | |
| Operating Expenses | |||
| Selling, general and administrative | 14,980 | 12,502 | |
| Research and development | 5,715 | 5,013 | |
| Amortization of acquisition-related assets | 985 | 985 | |
| Total operating expenses | 21,680 | 18,500 | |
| Loss from operations | (12,486) | (9,373) | |
| Interest expense, net | (3,450) | (3,568) | |
| Other income (expense), net | 6 | (2,570) | |
| Loss from continuing operations before income taxes | (15,930) | (15,511) | |
| Provision for (benefit from) income taxes | 20 | (8) | |
| Net loss from continuing operations | (15,950) | (15,503) | |
| Income from discontinued operations, net of tax attributable to NantHealth | — | 4 | |
| Net loss | (15,950) | (15,499) | |
| Net loss attributable to noncontrolling interests | — | (91) | |
| Net loss attributable to NantHealth | $ (15,950) | $ (15,408) | |
| Basic and diluted net loss per share attributable to NantHealth: | |||
| Total net loss per share – common stock | $ (0.14) | $ (0.14) | |
| Weighted average shares outstanding | |||
| Basic and diluted – common stock | 115,521,243 | 111,319,061 | |
NantHealth, Inc.
Non-GAAP Net Loss from Continuing Operations Attributable to NantHealth and
Non-GAAP Net Loss Per Share from Continuing Operations Attributable to NantHealth
(Dollars in thousands, except per share amounts)
(Unaudited)
| Three Months Ended
March 31, |
|||
| 2022 | 2021 | ||
| Net loss from continuing operations attributable to NantHealth | $ (15,950) | $ (15,412) | |
| Adjustments to GAAP net loss from continuing operations attributable to NantHealth: | |||
| Stock-based compensation expense from continuing operations | 1,390 | 883 | |
| Change in fair value of derivatives liability | — | (4) | |
| Change in fair value of Bookings Commitment | 94 | 2,463 | |
| Noncash interest expense related to convertible notes | 37 | 323 | |
| Intangible amortization from continuing operations | 2,232 | 2,212 | |
| Tax (benefit) provision resulting from certain noncash tax items | (40) | (43) | |
| Total adjustments to GAAP net loss from continuing operations attributable to NantHealth | 3,713 | 5,834 | |
| Net loss from continuing operations attributable to NantHealth – Non-GAAP | $ (12,237) | $ (9,578) | |
| Weighted average basis common shares outstanding | 115,521,243 | 111,319,061 | |
| Net loss per common share from continuing operations attributable to NantHealth – Non-GAAP | $ (0.11) | $ (0.09) | |
Reconciliation of Net Loss per Common Share from Continuing Operations Attributable to NantHealth to Net Loss per Common Share from Continuing Operations Attributable to NantHealth – Non-GAAP
(Unaudited)
| Three Months Ended
March 31, |
|||
| 2022 | 2021 | ||
| Net loss per common share from continuing operations attributable to NantHealth | $ (0.14) | $ (0.14) | |
| Adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth: | |||
| Stock-based compensation expense from continuing operations | 0.01 | 0.01 | |
| Change in fair value of derivatives liability | — | — | |
| Change in fair value of Bookings Commitment | — | 0.02 | |
| Noncash interest expense related to convertible notes | — | — | |
| Intangible amortization from continuing operations | 0.02 | 0.02 | |
| Tax (benefit) provision resulting from certain noncash tax items | — | — | |
| Total adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth | 0.03 | 0.05 | |
| Net loss per common share from continuing operations attributable to NantHealth – Non-GAAP | $ (0.11) | $ (0.09) | |